Moors & Cabot’s VanEck Biotech ETF BBH Stock Holding History

Moors & Cabot’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$539K	Buy	+2,205	New	+$492K	0.02%	545

Other funds holding BBH

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Paragon Private Wealth Management Lexington, Kentucky $326M AUM 26.55% 1-Year Est. Return

L.J. Altfest & Co New York $1.01B AUM 24.77% 1-Year Est. Return

Institute for Wealth Management Denver, Colorado $1.13B AUM 31.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Aspiriant LLC Los Angeles, California $4.08B AUM 12.02% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return

Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return

Flagship Harbor Advisors Boston, Massachusetts $2.69B AUM 15.82% 1-Year Est. Return

Moors & Cabot's BBH Position: Q3 2026 in Review

Moors & Cabot opened a new position in VanEck Biotech ETF (BBH) in Q3 2026: 2,205 shares worth $539K. The stake represents 0.02% of the portfolio and ranks #545 among its holdings.

47 funds tracked by Wall St. Rank hold BBH as of Q3 2026.

Moors & Cabot held 2,205 shares of VanEck Biotech ETF worth $539K as of Q3 2026.
VanEck Biotech ETF was a new Moors & Cabot position in Q3 2026.
VanEck Biotech ETF made up 0.02% of Moors & Cabot's portfolio in Q3 2026, its #545 holding.
47 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2026.

Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.